Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

NCT03488862 · clinicaltrials.gov ↗
COMPLETED
Status
34
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

UNC Lineberger Comprehensive Cancer Center